-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In recent decades, several targeted therapies -- biologics and small molecules -- have been successfully developed and approved for the treatment of moderate-to-severe psoriasis vulgar.
In this issue of the BMJ, Bregnhøj et al report results from a proof-of-concept, phase Ib study investigating the safety of the novel HSP90 inhibitor RGRN-305 in 11 patients with plaque psoriasis and effectiveness for 12 wee.
The authors also performed skin transcriptome analysis using microarrays, which showed early and sustained reduction of pathophysiologically significant inflammatory transcripts, including IL36G and CXCL8, and delayed downregulation of IL23/STAT3-driven activity in clinical responde.
NLRP3 gene polymorphisms have been reported to increase the risk of psoriasis in Swedes, but evidence for a central role of the NLRP3 inflammasome in human psoriasis is still lacki.
immunity
Taken together, these results still herald a new paradigm for the treatment of psorias.
precise
Source: Bachelez H, Is heat shock protein 90 inhibition a relevant treatment strategy for psoriasis? Br J Dermatol 2022 05;186(5)
Bachelez H, Is heat shock protein 90 inhibition a relevant treatment strategy for psoriasis? Br J Dermatol 2022 05;186(5)leave a message here